Reprogrammed Brain Cells Combat Alzheimer's Plaques
# Reprogrammed Brain Cells Combat Alzheimer's Plaques
Alzheimer's disease, affecting over 55 million people worldwide, is primarily characterized by the accumulation of beta-amyloid protein plaques in the brain. These deposits lead to progressive neuronal damage and cognitive decline. Despite decades of research, therapeutic options remain limited, and the precise mechanisms of action of certain recently approved molecules were not fully understood.
However, the years 2025 and 2026 witnessed two significant breakthroughs in the understanding and potential treatment of this neurodegenerative disease. These discoveries focus on reprogramming the brain's immune cells, microglia and astrocytes, to more effectively clear amyloid plaques. They open new avenues for more targeted and potentially less invasive immunotherapies.
One of these advancements clarified how an already approved monoclonal antibody, Lecanemab, functions by demonstrating how it activates microglia. Simultaneously, a new cellular immunotherapy approach, inspired by oncology, showed the ability of genetically modified astrocytes to substantially reduce amyloid plaques in mice, suggesting a promising path for single-injection treatments.
Microglial Cells, Ineffective Guardians of Neurons Against Amyloid
Amyloid plaques are protein aggregates that accumulate between neurons and are considered a pathological hallmark of Alzheimer's disease. Their presence disrupts neuronal communication and leads to cell death, contributing to the decline in cognitive functions. Within the brain, microglial cells play a front-line role in immune defense. They act as resident macrophages, patrolling brain tissue to clear cellular debris and pathogens.
In the face of amyloid plaques, microglia naturally cluster around these deposits. However, in the context of Alzheimer's disease, this response often proves insufficient to effectively clear the protein aggregates. Microglial cells fail to adequately phagocytose and degrade the plaques, leading to a persistent accumulation of toxic deposits. This observation has raised a central question for research: Is it possible to reprogram these cells to perform their clearing task more effectively?
This question is all the more pertinent as the precise mechanisms by which certain anti-amyloid therapies act remained partially understood. Understanding how to activate or "awaken" the clearing capabilities of microglia has become a central objective for the development of new therapeutic strategies targeting amyloid pathology.
Lecanemab Activates Microglia via its Fc Fragment, a Mechanism Elucidated in 2026
A discovery reported in March 2026 by researchers from the Vlaams Instituut voor Biotechnologie (VIB) and KU Leuven brought clarity to the function of Lecanemab, a monoclonal antibody approved by the FDA for Alzheimer's disease [1]. This study revealed that the efficacy of this antibody relies on its Fc fragment, a part of the molecule that interacts with immune cells. Lecanemab's Fc fragment acts as a trigger, stimulating the brain's microglial cells to clear amyloid plaques.
To reach this conclusion, scientists used a specially designed murine model of Alzheimer's, incorporating human microglial cells. This model allowed for the observation of human-specific cellular responses with previously unattainable resolution [1]. The study demonstrated that the Fc fragment is essential: without it, microglia remain inactive and fail to degrade plaques. Dr. Giulia Albertini, co-first author of the study, emphasized that "our study is the first to clearly demonstrate how this anti-amyloid antibody therapy works in Alzheimer’s disease. We show that the therapy’s efficacy relies on the Fc fragment of the antibody, which activates microglia to efficiently clear amyloid plaques" [1].
Microglial reprogramming induced by Lecanemab involves the activation of key cellular processes, notably phagocytosis, which is the ingestion of plaques by the cells, and lysosomal activity, which corresponds to their internal degradation. Advanced techniques, such as single-cell and spatial transcriptomics, allowed for the identification of a specific gene activity pattern in activated microglia, including high expression of the SPP1 gene, associated with efficient plaque clearance [1]. This detailed understanding of the mechanism of action provides a basis for optimizing existing treatments and developing new ones.
Directly Reprogramming Microglia Without Antibodies: A Future Possibility
The discovery of the crucial role of Lecanemab's Fc fragment in microglial activation has significant implications for the development of future therapies for Alzheimer's disease. It suggests that it might be possible to directly activate microglia to clear amyloid plaques, without necessarily resorting to monoclonal antibodies. Prof. Bart De Strooper, co-senior author of the study, stated that "this opens the way for future therapies that could activate microglia without requiring antibodies. Understanding the importance of the Fc fragment helps guide the design of next-generation Alzheimer's drugs" [1].
Current monoclonal antibody-based therapies, such as Lecanemab and Donanemab, have shown their ability to slow cognitive decline in some patients. However, they have limitations. They require frequent intravenous infusions, often every two weeks, which represents a logistical burden and significant cost. Furthermore, they are associated with a risk of amyloid-related imaging abnormalities (ARIA), which can manifest as cerebral edema or hemorrhages.
By directly targeting the signaling pathways activated by the Fc fragment, researchers could design smaller molecules or gene therapy approaches capable of stimulating microglia more selectively and potentially with fewer systemic side effects. The goal would be to replicate the beneficial effect of Lecanemab, but in a way that is more effective, less invasive, and safer for patients.
CAR-Astrocytes, a New Immunotherapy Inspired by Oncology
In parallel with the understanding of Lecanemab, a new cellular immunotherapy approach was developed in March 2026 by scientists at Washington University [2]. This method is directly inspired by chimeric antigen receptor T-cell (CAR T-cell) therapy, already used in oncology to reprogram immune cells to attack cancer cells. Here, the innovation consists of applying this principle to astrocytes, another type of glial cell present in the brain.
Researchers engineered genetically modified astrocytes, called CAR-astrocytes, to specifically target and clear beta-amyloid plaques [2]. To do this, they used a harmless virus as a vector to transfer a gene encoding a CAR to the astrocytes. This CAR enables the astrocytes to recognize and bind to amyloid proteins, thereby reprogramming them into "super cleaners" of these toxic aggregates. Marco Colonna, senior author of the study, stated that "this study marks the first successful attempt to engineer astrocytes to specifically target and clear beta-amyloid plaques in the brains of mice with Alzheimer’s disease" [2].
This approach represents a paradigm shift, as it not only activates an existing cellular response but genetically modifies cells to endow them with a new therapeutic function. By leveraging expertise gained in CAR T therapies, scientists are seeking to adapt these techniques to address neurodegenerative diseases, offering a new avenue for targeted and potentially durable treatments. The study was published in the journal Science [3].
A Single Injection Reduces Plaques by 50% in Mice
The preclinical results of CAR-astrocyte immunotherapy are promising. A single injection of this gene therapy prevented the development of amyloid plaques in young mice, suggesting prophylactic potential [2]. More significantly, in older mice that already had established plaques, the treatment led to an approximately 50% reduction in amyloid plaques [2]. This substantial reduction in protein deposits is comparable to, if not greater than, that observed with certain monoclonal antibody therapies requiring repeated administrations.
One of the advantages of this approach lies in its administration modality. Unlike monoclonal antibodies that require frequent infusions to maintain therapeutic levels, CAR-astrocyte therapy could potentially be administered in a single injection. David Holtzman, co-senior author of the study, emphasized this point by stating: "Consistent with antibody drug treatments, this new CAR-astrocyte immunotherapy is most effective when administered in the early stages of the disease. But where it differs, and where it could make a difference in clinical care, is in the single injection that successfully reduced the amount of harmful brain proteins in mice" [2].
The durability of the effect after a single injection, as well as the significant reduction in plaques, positions CAR-astrocytes as a potentially less invasive and more effective alternative for patients. If these results are confirmed in humans, this approach could significantly improve the quality of life for affected individuals, by reducing the frequency of treatments and potentially their systemic side effects.
Prospects for Combined Strategies and Personalized Medicine
The two advancements, though distinct in their cellular targets (microglia for Lecanemab, astrocytes for CAR immunotherapy), converge towards a common goal: activating or reprogramming the brain's resident immune cells to combat amyloid pathology. The differentiation of cellular targets opens prospects for combined therapeutic strategies. It is conceivable that a future approach could leverage the strengths of each cell type, simultaneously activating microglia and astrocytes for even more effective plaque clearance.
These discoveries have a significant impact on future Alzheimer's disease research. They guide the development of therapies towards gene therapy and cell reprogramming approaches, which could offer more targeted and durable solutions than current treatments. Understanding the precise molecular mechanisms of microglial activation by Lecanemab's Fc fragment, as well as the ability of CAR-astrocytes to target and degrade plaques, provides a roadmap for the design of new generation drugs.
